A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 23, Issue 9, 2011, Pages 1154-1162

  Juday, Timothy ^a   Grimm, Kristy ^a   Zoe Powers, Annette ^a   Willig, James ^b   Kim, Edward ^a  

^a BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

antiretroviral therapy; HIV 1 infection; treatment persistence

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; DARUNAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; COMORBIDITY; DRUG WITHDRAWAL; FEMALE; GENDER; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUBSTANCE ABUSE; UNITED STATES;

ADULT; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INSURANCE, HEALTH; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RITONAVIR; UNITED STATES;

EID: 80052112367     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121.2010.543884     Document Type: Article

References (19)

1. Ahdieh-Grant, L., Tarwater, P.M., Schneider, M.F., Anastos, K., Cohen, M., Khalsa, A., ⋯ Greenblat, R.M. & Women's Interagency HIV Study. (2005). Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. Journal of Acquired Immune Deficiency Syndrome, 38(4), 500-503. (Pubitemid 40381561)
2. Board on Health Promotion and Disease Prevention [HPDP]. 2005). Public financing and delivery of HIV/ AIDS care: Securing the legacy of Ryan white. Washington, DC: The Institute of Medicine, The National Academies Press.
3. Braithwaite, R.S., Kozal, M.J., Chang, C.C., Roberts, M.S., Fultz, S.L., Goetz, M.B., ⋯ Justice, A.C. (2007). Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS (London, England), 21(12), 1579-1589. (Pubitemid 47075479)
4. Charlson, M.E., Pompei, P., Ales, K.L., & MacKenzie, C.R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases, 40(5), 373-383. (Pubitemid 17055592)
5. Clark, R.A., & Squires, K.E. (2005). Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Review of Anti-Infective Therapy, 3(2), 213-227. (Pubitemid 40590327)
6. Cramer, J.A., Roy, A., Burrell, A., Fairchild, C.J., Fuldeore, M.J., Ollendorf, D.A., & Wong, P.K. (2008). Medication compliance and persistence: Terminology and definitions. Value Health, 11(1), 44-47. (Pubitemid 351160875)
7. Crystal, S., Sambamoorthi, U., Moynihan, P.J., & McSpiritt, E. (2001). Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. Journal of General Internal Medicine, 16(12), 850-859. (Pubitemid 34015701)
8. Domingo, P., Suarez-Lozano, I., Torres, F., Teira, R., Lopez-Aldeguer, J., Vidal, F., ⋯ Garrido, M. (2008). First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: The SUSKA study, a non-randomized comparison from the VACH cohort. Journal of Antimicrobial Chemotherapy, 61(6), 1348-1358. (Pubitemid 351753607)
9. Elzi, L., Marzolini, C., Furrer, H., Ledergerber, B., Cavassini, M., Hirschel, B., ⋯ Battegay, M. & Swiss HIV Cohort study. (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1), 57-65.
10. Glass, T.R., Battegay, M., Cavassini, M., De Geest, S., Furrer, H., Vernazza, P.L., ⋯ Bucher, H.C. & Swiss HIV Cohort Study. (2010). Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 54(2), 197-203.
11. Kempf, M.C., Pisu, M., Dumcheva, A., Westfall, A.O., Kilby, J.M., & Saag, M.S. (2009). Gender differences in discontinuation of antiretroviral treatment regimens. Journal of Acquired Immune Deficiency Syndrome, 52(3), 336-341.
12. Lazo, M., Gange, S.J., Wilson, T.E., Anastos, K., Ostrow, D.G., Witt, M.D., & Jacobson, L.P. (2007). Patterns and predictors of changes in adherence to highly active antiretroviral therapy: Longitudinal study of men and women. Clinical Infectious Diseases, 45(10), 1377-1385. (Pubitemid 351411918)
13. Li, X., Margolick, J.B., Conover, C.S., Badri, S., Riddler, S.A., Witt, M.D., & Jocobson, L.P. (2005). Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. Journal of Acquired Immune Deficiency Syndrome, 38(3), 320-328. (Pubitemid 40333499)
14. Mocroft, A., Youle, M., Moore, A., Sabin, C.A., Madge, S., Lepri, A.C., ⋯ Phillips, A.N. (2001). Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre. AIDS (London, England), 15(2), 185-194. (Pubitemid 32142293)
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2009, December, 1). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Retrieved from http://www.aidsinfo.nih.gov/Content Files/AdultandAdolescentGL.pdf
16. Spire, B., Carrieri, P., Garzot, M.A., L'henaff, M., & Obadia, Y. (2004). Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care, 16(5), 558-564. (Pubitemid 38918087)
17. van Roon, E.N., Verzijl, J.M., Juttmann, J.R., Lenderink, A.W., Blans, M.J., & Egberts, A.C. (1999). Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 20(3), 290-294. (Pubitemid 29156968)
18. Vo, T.T., Ledergerber, B., Keiser, O., Hirschel, B., Furrer, H., Battegay, M., ⋯ Weber, R. & Swiss HIV Cohort Study. (2008). Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 197(12), 1685-1694. (Pubitemid 351919632)
19. Willig, J.H., Abroms, S., Westfall, A.O., Routman, J., Adusumilli, S., Varshney, M., ⋯ Mugavero, M.J. (2008). Increased regimen durability in the era of oncedaily fixed-dose combination antiretroviral therapy. AIDS (London, England), 22(15), 1951-1960.